Nephroprotective Effect Assessment From Arid Lands Fruits Extracts in an Experimental Model With Cisplatine-Induced Nephrotoxicity

Abstract

Abstract Objectives The study aimed to assess the nephroprotective effect of Escontria chiotilla, Myrtillocactus geometrizans, and Stenocereus griseus extracts. Methods Forty male Wistar rats (200–250 g) were randomly divided into 8 groups. The vehicle (V) and cisplatin (CP) groups were administered (i.p.) with saline solution 0.09% and a dose of 6.5 mg/Kg, respectively. Three groups were administered by gavage (p.o.) with 4 mL/24hr during 7 days of each extract Escontria chiotilla (J), Myrtillocactus geometrizans (G), and Stenocereus griseus (P). The rest of the groups were administered with CP plus J, G, or P at same doses. Fruit extracts were administrated 72 h before and after CP administration. In the end, blood samples were collected from aorta and both kidneys were removed to carry out physiological and biochemistry studies. The serum creatinine (Cr) and Blood Urea Nitrogen (BUN) levels were determined. The malondialdehyde (MDA) levels were quantified in kidney tissue. For the statistical analysis, an ANOVA followed by a Bonferroni's multiple comparisons test was performed. A P ≤ 0.05 value was considered statistically significant. Data are presented as mean ± SEM. Results Rats from the CP group had elevated levels of Cr and BUN serum, and MDA renal levels vs. V. The Cr and BUN serum were significantly reduced in groups with fruit extracts (0.58 ± 0.01, 0.66 ± 0.03, 0.57 ± 0.03 vs. 1.4 ± 0.06; and 22 ± 1.2, 26 ± 3.5, 20 ± 2.1 vs. 58 ± 4.8 with J, G and P vs CP, respectively) same effect was observed in MDA levels where reduction of 55, 64, 66% with J, G and P, was seen. Conclusions Our results showed that extracts from dry land fruits had nephroprotective effects in the CP nephrotoxicity model by reduction of the serum creatinine, BUN and MDA levels. Those effects had almost the same magnitude, however, is a need to perform more experiments to know the mechanisms involved. Funding Sources IPICYT-CONACYT.